Intravenous Immunoglobulin in the Treatment of Neurological Diseases.
10.26815/jkcns.2018.26.1.1
- Author:
Se Hee KIM
1
;
Young Mock LEE
Author Information
1. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea. ymleemd@yuhs.ac
- Publication Type:Review
- Keywords:
Intravenous immunoglobulin;
Neurology;
Chronic inflammatory demyelinating polyradiculoneuropathy;
Guillain–Barré syndrome
- MeSH:
Humans;
Immunoglobulins*;
Immunoglobulins, Intravenous;
Neurology;
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- From:
Journal of the Korean Child Neurology Society
2018;26(1):1-6
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Intravenous immunoglobulin (IVIG) is used in treating many cases of autoimmune and inflammatory conditions thanks to its multiple anti-inflammatory and immunomodulatory properties. The clinical use of IVIG has been for the patients with primary immunodeficiencies, but lately it is expanding its usage to the realms of treating patients with neurological conditions. Both the efficacy and safety of IVIG treatment in chronic inflammatory demyelinating polyradiculoneuropathy and Guillain–Barré syndrome have been studied successfully. However, the use of IVIG treatment in other neurological conditions still remains investigational despite several successful reports. Considerable numbers of mechanisms have been suggested in order to explain the effects of IVIG, but the exact mechanisms are not understood yet. This review covers the new developments in clinical fields and the possible ways in which IVIG could help in the future.
